Drug Search Results
More Filters [+]

PF-03654764

Alternative Names: pf-03654764, pf03654764, pf 03654764
Latest Update: 2019-02-11
Latest Update Note: Clinical Trial Update

Product Description

PF-03654764 should reduce the symptoms of allergic rhinitis (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT01033396)

Mechanisms of Action: H3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-03654764

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Rhinitis, Allergic

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B0711006

P1

Terminated

Healthy Volunteers

2010-06-04

28%

B0711005

P2

Completed

Rhinitis, Allergic

2010-05-01

B0711002

P1

Completed

Healthy Volunteers

2009-12-01

Recent News Events

Date

Type

Title